{"title_page": "ABT-202", "text_new": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 477235049\n| IUPAC_name = (''R'')-1-(Pyridin-3-yl)pyrrolidin-3-amine\n| image = ABT-202.svg\n| width = 175\n\n<!--Clinical data-->\n| tradename =\n| routes_of_administration =\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 309959-34-0\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = RJ89CX560B\n| ATC_suffix = None\n| PubChem = 39220800\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| ChemSpiderID = 16397614\n\n<!--Chemical data-->\n| C=9 | H=13 | N=3 \n| molecular_weight = 163.219\n| smiles = N[C@@H]1CCN(C2=CC=CN=C2)C1\n| StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C9H13N3/c10-8-3-5-12(7-8)9-2-1-4-11-6-9/h1-2,4,6,8H,3,5,7,10H2/t8-/m1/s1\n| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = LVGMMVAWLISWJD-MRVPVSSYSA-N\n}}\n\n'''ABT-202''' is a drug developed by [[Abbott Laboratories|Abbott]], which acts as an agonist at neural [[nicotinic acetylcholine receptor]]s and has been researched for use as an [[analgesic]], although it has not passed [[clinical trials]].<ref>{{cite journal | vauthors = Jain KK | title = Modulators of nicotinic acetylcholine receptors as analgesics | journal = Current Opinion in Investigational Drugs | volume = 5 | issue = 1 | pages = 76\u201381 | date = January 2004 | pmid = 14983978 }}</ref><ref>{{cite journal | vauthors = Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F | title = Central nicotinic receptors: structure, function, ligands, and therapeutic potential | journal = ChemMedChem | volume = 2 | issue = 6 | pages = 746\u201367 | date = June 2007 | pmid = 17295372 | doi = 10.1002/cmdc.200600207 }}</ref><ref>{{cite journal | vauthors = Xu N, Kim GE, Gregg H, Wagdy A, Swaine BA, Chang MS, El-Shourbagy TA | title = Automated 96-well liquid-liquid back extraction liquid chromatography-tandem mass spectrometry method for the determination of ABT-202 in human plasma | journal = Journal of Pharmaceutical and Biomedical Analysis | volume = 36 | issue = 1 | pages = 189\u201395 | date = September 2004 | pmid = 15351065 | doi = 10.1016/j.jpba.2004.05.013 }}</ref>\n\n== References ==\n{{Reflist|2}}\n\n{{Stimulants}}\n{{Analgesics}}\n{{Nicotinic acetylcholine receptor modulators}}\n\n{{DEFAULTSORT:Abt-202}}\n[[Category:Analgesics]]\n[[Category:Nicotinic agonists]]\n[[Category:Pyridines]]\n[[Category:Pyrrolidines]]\n[[Category:Stimulants]]\n\n{{analgesic-stub}}\n", "text_old": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 477235049\n| IUPAC_name = (''R'')-1-(Pyridin-3-yl)pyrrolidin-3-amine\n| image = ABT-202.svg\n| width = 175\n\n<!--Clinical data-->\n| tradename =\n| routes_of_administration =\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 309959-34-0\n| ATC_suffix = None\n| PubChem = 39220800\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| ChemSpiderID = 16397614\n\n<!--Chemical data-->\n| C=9 | H=13 | N=3 \n| molecular_weight = 163.219\n| smiles = N[C@@H]1CCN(C2=CC=CN=C2)C1\n| StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C9H13N3/c10-8-3-5-12(7-8)9-2-1-4-11-6-9/h1-2,4,6,8H,3,5,7,10H2/t8-/m1/s1\n| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = LVGMMVAWLISWJD-MRVPVSSYSA-N\n}}\n\n'''ABT-202''' is a drug developed by [[Abbott Laboratories|Abbott]], which acts as an agonist at neural [[nicotinic acetylcholine receptor]]s and has been researched for use as an [[analgesic]], although it has not passed [[clinical trials]].<ref>{{cite journal | vauthors = Jain KK | title = Modulators of nicotinic acetylcholine receptors as analgesics | journal = Current Opinion in Investigational Drugs | volume = 5 | issue = 1 | pages = 76\u201381 | date = January 2004 | pmid = 14983978 }}</ref><ref>{{cite journal | vauthors = Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F | title = Central nicotinic receptors: structure, function, ligands, and therapeutic potential | journal = ChemMedChem | volume = 2 | issue = 6 | pages = 746\u201367 | date = June 2007 | pmid = 17295372 | doi = 10.1002/cmdc.200600207 }}</ref><ref>{{cite journal | vauthors = Xu N, Kim GE, Gregg H, Wagdy A, Swaine BA, Chang MS, El-Shourbagy TA | title = Automated 96-well liquid-liquid back extraction liquid chromatography-tandem mass spectrometry method for the determination of ABT-202 in human plasma | journal = Journal of Pharmaceutical and Biomedical Analysis | volume = 36 | issue = 1 | pages = 189\u201395 | date = September 2004 | pmid = 15351065 | doi = 10.1016/j.jpba.2004.05.013 }}</ref>\n\n== References ==\n{{Reflist|2}}\n\n{{Stimulants}}\n{{Analgesics}}\n{{Nicotinic acetylcholine receptor modulators}}\n\n{{DEFAULTSORT:Abt-202}}\n[[Category:Analgesics]]\n[[Category:Nicotinic agonists]]\n[[Category:Pyridines]]\n[[Category:Pyrrolidines]]\n[[Category:Stimulants]]\n\n{{analgesic-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/ABT-202"}
